Clinical validation and adoption are some of the key measures of success for FGS and other innovative approaches in medicine. Early successes should pave the way for accelerated translation of subsequent technologies.  And ‚Äú‚Ķalthough regulatory approval represents a real and complex challenge, adequate reimbursement of FGS techniques is of equal, if not greater, concern for broad clinical adoption by all but the most academically motivated institutions. Here, translational researchers and commercial entities are challenged to develop realistic financial models to demonstrate a compelling value proposition to payers. Such models should extend beyond the immediate financial benefits ‚Ķ‚Ķ. Ultimately, reimbursement strategies will require careful and precise definition of these clinically significant changes, along with the attendant benefits and risks to the patient, as viewed through the lens of the economics of care.

Recommended Posts